{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:46:28Z","timestamp":1769121988136,"version":"3.49.0"},"reference-count":38,"publisher":"e-Century Publishing Corporation","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/irzd9853","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T08:57:12Z","timestamp":1761728232000},"page":"7545-7556","source":"Crossref","is-referenced-by-count":0,"title":["Clinical effect of donepezil hydrochloride in the treatment of Parkinson's disease patients: a meta-analysis"],"prefix":"10.62347","volume":"17","author":[{"given":"Min","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41531-025-00980-7","article-title":"New insights into pathogenisis and therapies of P2X7R in Parkinson’s disease","volume":"11","author":"Wei","year":"2025","unstructured":"Wei S, Song X, Mou Y, Yang T, Wang Y, Wang H, Ren C and Song X. New insights into pathogenisis and therapies of P2X7R in Parkinson’s disease. NPJ Parkinsons Dis 2025; 11: 108.","journal-title":"NPJ Parkinsons Dis"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40035-019-0162-z","article-title":"Parkinson’s disease in China: a forty-year growing track of bedside work","volume":"8","author":"Li","year":"2019","unstructured":"Li G, Ma J, Cui S, He Y, Xiao Q, Liu J and Chen S. Parkinson’s disease in China: a forty-year growing track of bedside work. Transl Neurodegener 2019; 8: 22.","journal-title":"Transl Neurodegener"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/brainsci13020157","article-title":"Age at onset influences progression of motor and non-motor symptoms during the early stage of parkinson’s disease: a monocentric retrospective study","volume":"13","author":"Carolis L","year":"2023","unstructured":"De Carolis L, Galli S, Bianchini E, Rinaldi D, Raju M, Caliò B, Alborghetti M and Pontieri FE. Age at onset influences progression of motor and non-motor symptoms during the early stage of parkinson’s disease: a monocentric retrospective study. Brain Sci 2023; 13: 157.","journal-title":"Brain Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/mds.27115","article-title":"Past, present, and future of parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy","volume":"32","author":"Obeso","year":"2017","unstructured":"Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV and Stoessl AJ. Past, present, and future of parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Mov Disord 2017; 32: 1264-1310.","journal-title":"Mov Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson’s disease","volume":"397","author":"BR","year":"2021","unstructured":"Bloem BR, Okun MS and Klein C. Parkinson’s disease. Lancet 2021; 397: 2284-2303.","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","unstructured":"Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K and Weintraub D. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 2021; 7: 47.","journal-title":"Nat Rev Dis Primers"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2169\/internalmedicine.8940-21","article-title":"Recent advances in drug therapy for parkinson’s disease","volume":"62","author":"Murakami","year":"2023","unstructured":"Murakami H, Shiraishi T, Umehara T, Omoto S and Iguchi Y. Recent advances in drug therapy for parkinson’s disease. Intern Med 2023; 62: 33-42.","journal-title":"Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.31083\/j.jin2205132","article-title":"Pain in parkinson’s disease: pathophysiology, classification and treatment","volume":"22","author":"Cattaneo","year":"2023","unstructured":"Cattaneo C and Jost WH. Pain in parkinson’s disease: pathophysiology, classification and treatment. J Integr Neurosci 2023; 22: 132.","journal-title":"J Integr Neurosci"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Pooladgar P, Sakhabakhsh M, Taghva A and Soleiman-Meigooni S. Donepezil beyond alzheimer’s disease? A narrative review of therapeutic potentials of donepezil in different diseases. Iran J Pharm Res 2022; 21: e128408.","DOI":"10.5812\/ijpr-128408"},{"key":"ref9","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ and Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane 2024. Available from www.training.cochrane.org\/handbook."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","article-title":"Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study","volume":"72","author":"Aarsland","year":"2002","unstructured":"Aarsland D, Laake K, Larsen JP and Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708-712.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/mds.25098","article-title":"Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study","volume":"27","author":"Dubois","year":"2012","unstructured":"Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, Hsu T and Moline ML. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012; 27: 1230-1238.","journal-title":"Mov Disord"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/gps.993","article-title":"Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease","volume":"19","author":"Leroi","year":"2004","unstructured":"Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R and Marsh L. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 2004; 19: 1-8.","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","article-title":"Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study","volume":"76","author":"Ravina","year":"2005","unstructured":"Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S and Simuni T. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934-939.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1136\/jnnp-2018-318107","article-title":"Early use of donepezil against psychosis and cognitive decline in Parkinson’s disease: a randomised controlled trial for 2 years","volume":"89","author":"Sawada","year":"2018","unstructured":"Sawada H, Oeda T, Kohsaka M, Umemura A, Tomita S, Park K, Mizoguchi K, Matsuo H, Hasegawa K, Fujimura H, Sugiyama H, Nakamura M, Kikuchi S, Yamamoto K, Fukuda T, Ito S, Goto M, Kiyohara K and Kawamura T. Early use of donepezil against psychosis and cognitive decline in Parkinson’s disease: a randomised controlled trial for 2 years. J Neurol Neurosurg Psychiatry 2018; 89: 1332-1340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/psyg.13091","article-title":"Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12-week multicentre, randomised, double-blind, and placebo-controlled phase IV study","volume":"24","author":"Mori","year":"2024","unstructured":"Mori E, Ikeda M, Iseki E, Katayama S, Nagahama Y, Ohdake M and Takase T. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12-week multicentre, randomised, double-blind, and placebo-controlled phase IV study. Psychogeriatrics 2024; 24: 542-554.","journal-title":"Psychogeriatrics"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"101571","DOI":"10.1016\/j.eclinm.2022.101571","article-title":"Effect of donepezil for dementia prevention in Parkinson’s disease with severe hyposmia (The DASH-PD study): a randomized long-term placebo-controlled trial","volume":"51","author":"Baba","year":"2022","unstructured":"Baba T, Takeda A, Murakami A, Koga T, Isomura T and Mori E; DASH-PD study group. Effect of donepezil for dementia prevention in Parkinson’s disease with severe hyposmia (The DASH-PD study): a randomized long-term placebo-controlled trial. EClinicalMedicine 2022; 51: 101571.","journal-title":"EClinicalMedicine"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial","volume":"7","author":"Ikeda","year":"2015","unstructured":"Ikeda M, Mori E, Matsuo K, Nakagawa M and Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther 2015; 7: 4.","journal-title":"Alzheimers Res Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ana.23557","article-title":"Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial","volume":"72","author":"Mori","year":"2012","unstructured":"Mori E, Ikeda M and Kosaka K; Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012; 72: 41-52.","journal-title":"Ann Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1038\/s41598-021-84243-4","article-title":"Donepezil for mild cognitive impairment in Parkinson’s disease","volume":"11","author":"Baik","year":"2021","unstructured":"Baik K, Kim SM, Jung JH, Lee YH, Chung SJ, Yoo HS, Ye BS, Lee PH, Sohn YH, Kang SW and Kang SY. Donepezil for mild cognitive impairment in Parkinson’s disease. Sci Rep 2021; 11: 4734.","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(21)00330-6","article-title":"The neuropsychiatry of Parkinson’s disease: advances and challenges","volume":"21","author":"Weintraub","year":"2022","unstructured":"Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M and Schrag A. The neuropsychiatry of Parkinson’s disease: advances and challenges. Lancet Neurol 2022; 21: 89-102.","journal-title":"Lancet Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/cells9071687","article-title":"Inflammation in parkinson’s disease: mechanisms and therapeutic implications","volume":"9","author":"Pajares","year":"2020","unstructured":"Pajares M, I Rojo A, Manda G, Boscá L and Cuadrado A. Inflammation in parkinson’s disease: mechanisms and therapeutic implications. Cells 2020; 9: 1687.","journal-title":"Cells"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","unstructured":"Armstrong MJ and Okun MS. Diagnosis and treatment of parkinson disease: a review. JAMA 2020; 323: 548-560.","journal-title":"JAMA"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41531-021-00207-5","article-title":"Longitudinal evolution of non-motor symptoms in early Parkinson’s disease: a 3-year prospective cohort study","volume":"7","author":"Ou","year":"2021","unstructured":"Ou R, Hou Y, Wei Q, Lin J, Liu K, Zhang L, Jiang Z, Cao B, Zhao B, Song W and Shang H. Longitudinal evolution of non-motor symptoms in early Parkinson’s disease: a 3-year prospective cohort study. NPJ Parkinsons Dis 2021; 7: 58.","journal-title":"NPJ Parkinsons Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson’s disease","volume":"403","author":"Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM and Williams-Gray CH. The pathogenesis of Parkinson’s disease. Lancet 2024; 403: 293-304.","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"DM 3rd","year":"2023","unstructured":"Wilson DM 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM and Dewachter I. Hallmarks of neurodegenerative diseases. Cell 2023; 186: 693-714.","journal-title":"Cell"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Witzig V, Pjontek R, Tan SKH, Schulz JB and Holtbernd F. Modulating the cholinergic system-Novel targets for deep brain stimulation in Parkinson’s disease. J Neurochem 2025; 169: e16264.","DOI":"10.1111\/jnc.16264"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/bs.pbr.2022.01.011","article-title":"Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson’s disease","volume":"269","author":"Albin","year":"2022","unstructured":"Albin RL, van der Zee S, van Laar T, Sarter M, Lustig C, Muller MLTM and Bohnen NI. Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson’s disease. Prog Brain Res 2022; 269: 345-371.","journal-title":"Prog Brain Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/psyg.13101","article-title":"Donepezil for dementia with Lewy bodies: meta-analysis of multicentre, randomised, double-blind, placebo-controlled phase II, III, and, IV studies","volume":"24","author":"Mori","year":"2024","unstructured":"Mori E, Ikeda M and Ohdake M. Donepezil for dementia with Lewy bodies: meta-analysis of multicentre, randomised, double-blind, placebo-controlled phase II, III, and, IV studies. Psychogeriatrics 2024; 24: 589-596.","journal-title":"Psychogeriatrics"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Meng YH, Wang PP, Song YX and Wang JH. Cholinesterase inhibitors and memantine for Parkinson’s disease dementia and Lewy body dementia: a meta-analysis. Exp Ther Med 2019; 17: 1611-1624.","DOI":"10.3892\/etm.2018.7129"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jnnp-2014-308764","article-title":"Cholinesterase inhibitors for Parkinson’s disease: a systematic review and meta-analysis","volume":"86","author":"Pagano","year":"2015","unstructured":"Pagano G, Rengo G, Pasqualetti G, Femminella GD, Monzani F, Ferrara N and Tagliati M. Cholinesterase inhibitors for Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015; 86: 767-773.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.encep.2021.08.014","article-title":"Les troubles du sommeil chez les patients atteints d’un trouble neurocognitif [Sleep disorders in patients with a neurocognitive disorder]","volume":"48","author":"Moderie","year":"2022","unstructured":"Moderie C, Carrier J and Dang-Vu TT. Les troubles du sommeil chez les patients atteints d’un trouble neurocognitif [Sleep disorders in patients with a neurocognitive disorder]. Encephale 2022; 48: 325-334.","journal-title":"Encephale"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40266-023-01065-x","article-title":"Psychiatric adverse events of acetylcholinesterase inhibitors in alzheimer’s disease and Parkinson’s dementia: systematic review and meta-analysis","volume":"40","author":"Bittner","year":"2023","unstructured":"Bittner N, Funk CSM, Schmidt A, Bermpohl F, Brandl EJ, Algharably EEA, Kreutz R and Riemer TG. Psychiatric adverse events of acetylcholinesterase inhibitors in alzheimer’s disease and Parkinson’s dementia: systematic review and meta-analysis. Drugs Aging 2023; 40: 953-964.","journal-title":"Drugs Aging"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/JCP.0000000000001901","article-title":"Late recognition of cholinergic delirium in patient on donepezil combination treatment","volume":"44","author":"Gwynn","year":"2024","unstructured":"Gwynn N, Lindenmayer JP, Boes T and Pitalo C. Late recognition of cholinergic delirium in patient on donepezil combination treatment. J Clin Psychopharmacol 2024; 44: 521-522.","journal-title":"J Clin Psychopharmacol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/alz.12807","article-title":"Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium","volume":"19","author":"OJ","year":"2023","unstructured":"Lieberman OJ, Lee S and Zabinski J. Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium. Alzheimers Dement 2023; 19: 1742-1751.","journal-title":"Alzheimers Dement"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1111\/bph.15940","article-title":"Donepezil inhibits neuromuscular junctional acetylcholinesterase and enhances synaptic transmission and function in isolated skeletal muscle","volume":"179","author":"Redman","year":"2022","unstructured":"Redman RR, Mackenzie H, Dissanayake KN, Eddleston M and Ribchester RR. Donepezil inhibits neuromuscular junctional acetylcholinesterase and enhances synaptic transmission and function in isolated skeletal muscle. Br J Pharmacol 2022; 179: 5273-5289.","journal-title":"Br J Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1179\/acb.2008.066","article-title":"Donepezil-related toxic hepatitis","volume":"63","author":"Dierckx","year":"2008","unstructured":"Dierckx RI and Vandewoude MF. Donepezil-related toxic hepatitis. Acta Clin Belg 2008; 63: 339-342.","journal-title":"Acta Clin Belg"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1439115","DOI":"10.3389\/fphar.2024.1439115","article-title":"Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023","volume":"15","author":"Yang","year":"2024","unstructured":"Yang Y, Wei S, Tian H, Cheng J, Zhong Y, Zhong X, Huang D, Jiang C and Ke X. Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023. Front Pharmacol 2024; 15: 1439115.","journal-title":"Front Pharmacol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/10\/ajtr0167123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:36:36Z","timestamp":1769063796000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/10\/ajtr0167123.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/irzd9853","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}